Sign up Australia
Proactive Investors - Run By Investors For Investors

Genetic Signatures’ clinical trials demonstrate product efficacy

John Melki, chief executive officer of Genetic Signatures Ltd (ASX:GSS), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney.

Genetic Signatures is developing and commercialising a platform technology called 3Base which is applicable to all specimen types, and compatible with DNA, RNA and nucleic acid detection technology. The company’s lead product offering is the EasyScreen series of tests, used for rapidly detecting infectious diseases. The polymerase chain reaction-based products are used in hospitals and pathology laboratories in regions across the world, including in Australia and New Zealand, Israel and Europe, the US and North America and other nations.

 
Meet Great Boulder Resources Ltd, Mainstream Group Holdings Ltd, Blackstone Minerals Ltd, Pacific American Coal Ltd and Reward Minerals Ltd at our event, Sydney , 19 November 2018. Register here »
View full GSS profile View Profile

Genetic Signatures Ltd Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use